A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer

被引：1
|
作者：
Chigusa Morizane
Makoto Ueno
Masafumi Ikeda
Kentaro Sudo
Yoshinori Hirashima
Masataka Kuroda
Shinji Ueno
Takuji Okusaka
Junji Furuse
机构：
[1] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology
[2] Hepatobiliary and Pancreatic Medical Oncology Division,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Hepatobiliary and Pancreatic Oncology
[4] National Cancer Center Hospital East,Department of Gastroenterology
[5] Chiba Cancer Center,Clinical Development Headquarters
[6] Ono Pharmaceutical Co.,Department of Medical Oncology
[7] Ltd.,undefined
[8] Kyorin University Faculty of Medicine,undefined
[9] Kanagawa Cancer Center,undefined
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-023-00028-4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Multicenter retrospective analysis of original versus modified FOLFIRINOX in metastatic pancreatic cancer: Results of the NAPOLEON study
    Nakazawa, Junichi
    Tsuruta, Nobuhiro
    Shimokawa, Mototsugu
    Kawahira, Machiko
    Arima, Shiho
    Ido, Akio
    Koga, Futa
    Ueda, Yujiro
    Komori, Azusa
    Otsu, Satoshi
    Fukahori, Masaru
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Otsuka, Taiga
    Shirakawa, Tsuyoshi
    Mitsugi, Kenji
    ONCOLOGY, 2023, 101 (01) : 22 - 31
  • [22] FOLFIRINOX in locally advanced or metastatic pancreatic cancer
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Guimaraes, Alexander R.
    Sahani, Dushyant
    Clark, Jeffrey W.
    Ryan, David P.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [23] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Vaccaro, Vanja
    Sperduti, Isabella
    Milella, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08): : 768 - 769
  • [24] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19): : 1817 - 1825
  • [25] Metastatic pancreatic cancer—is FOLFIRINOX the new standard?
    M. Wasif Saif
    John Chabot
    Nature Reviews Clinical Oncology, 2011, 8 : 452 - 453
  • [26] Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC)
    James, Edward Samuel
    Yao, Xiaopan
    Cong, Xiangyu
    Li, Jia
    Hahn, Carol
    Kaley, Kristin
    Kortmansky, Jeremy S.
    Fischbach, Neal A.
    Chang, Bryan William
    Salem, Ronald R.
    Cha, Charles
    Stein, Stacey
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study
    Sharma, Atul
    Pramanik, Raja
    Kumar, Akash
    Pathy, Sushmita
    Kumar, Sunil
    Bhoriwal, Sandeep
    Thulkar, Sanjay
    Dash, Nihar Ranjan
    Pal, Sujoy
    Choudhary, Priyanshu
    Pawar, Satyajit
    Kumar, Rakesh
    Gupta, Gaurav
    JCO GLOBAL ONCOLOGY, 2021, 7 : 820 - 826
  • [28] Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC)
    James, Edward Samuel
    Yao, Xiaopan
    Cong, Xiangyu
    Stein, Stacey
    Kaley, Kristin
    Hahn, Carol
    Cha, Charles
    Salem, Ronald R.
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC).
    Stein, Stacey
    Cong, Xiangyu
    Yao, Xiaopan
    Hahn, Carol
    Li, Jia
    Kortmansky, Jeremy S.
    Chang, Bryan William
    Cha, Charles
    Salem, Ronald R.
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Phase 2 study of 1st-line modified FOLFIRINOX in unresectable advanced pancreatic cancer: Multicenter prospective study
    Yoshida, Kensaku
    Iwashita, Takuji
    Uemura, Shinya
    Maruta, Akinori
    Shimizu, Masahito
    Iwata, Keisuke
    Mukai, Tsuyoshi
    ANNALS OF ONCOLOGY, 2017, 28
12345